A new vaccine platform for fighting emerging viruses
A Self-Adjuvanting Virus Like Particle Vaccine Platform for Emerging Viruses
This study is testing a new type of vaccine that uses special particles to help your body fight off new viruses better, so you can have a stronger and longer-lasting immune response.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11092746 on NIH RePORTER |
What this research studies
This research focuses on developing a novel vaccine platform that utilizes virus-like particles to enhance the immune response against emerging viruses. By leveraging the protein Stimulator of Interferon Genes (STING), the project aims to improve vaccine efficacy through a self-adjuvanting mechanism. The approach involves creating cell lines that produce immunogenic particles capable of stimulating the immune system more effectively than traditional vaccines. Patients may benefit from a more robust and long-lasting immune response to viral infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of exposure to emerging viral infections, such as healthcare workers or those living in endemic areas.
Not a fit: Patients who are not at risk of emerging viral infections or those with contraindications to vaccination may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that provide better protection against emerging viral infections.
How similar studies have performed: Other research has shown promise in using STING activation to enhance vaccine responses, indicating that this approach could be a significant advancement in vaccine development.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Defilippis, Victor Robert — Oregon Health & Science University
- Study coordinator: Defilippis, Victor Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.